CardioKinetix has completed a $50 million financing led by Edwards Lifesciences Corporation, with participation from existing investors U.S. Venture Partners, Tekla Healthcare Investors, Tekla Life Sciences Investors SV Life Sciences, Panorama Capital, New Leaf Venture Partners, and Lexington Private Equity.

CardioKinetix has also entered into an agreement that provides Edwards Lifesciences the right to acquire CardioKinetix based on future regulatory milestones.

This financing provides the company with the capital necessary to complete the PARACHUTE IV randomized pivotal clinical trial of the Parachute Ventricular Partitioning Device for the treatment of heart failure.

The financing will also enable CardioKinetix to pursue international market development efforts in key geographies.

For further deal information visit Current Agreements (subscription required)

Related

Report:   Top 50 Big Pharma Partnering and M&A Deal Trends

Report:   Top 50 Big Biotech Partnering and M&A Deal Trends

Browse: Complete Current Partnering report catalog